T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non–small cell lung cancer  by Carbone, Emanuela et al.
Objective: Among the TNM criteria, tumor size is a well-assessed factor in the
prognosis of small tumors. A 3-cm cutoff point separates T1 from T2 tumors,
whereas a size larger than 3 cm is not ascribed any prognostic value. Instead, N2 is
considered to be the worst prognostic factor for intrathoracic extended disease.
Method: The prognosis of 545 patients with non–small cell lung cancer larger than
3 cm in diameter (T2, T3, and T4) was studied. These tumors were completely
resected by pneumonectomy (n = 126) or lobectomy (n = 411) or were partially
resected (n = 8). Survivals were compared according to the following factors: tumor
size (3.1-5 cm, 5.1-7 cm, >7 cm), nodal status, age, sex, histologic type, degree of
pleural involvement, operative procedure, stage, and T factor. For the multivariate
analysis, the Cox proportional hazard model was used with the same variables. 
Results: The univariate analysis showed that age, sex, degree of pleural involvement,
operative procedure, tumor size, nodal status, and stage were all significant prog-
nostic factors. Further comparison of survival between different tumor sizes (≤5 cm
vs >5 cm) in the same nodal category demonstrated a significantly poor prognosis
for larger tumors in N0 (P = .00374) and N2+N3 (P = .0157), but not in N1 (P =
.3452). T2 tumors (n = 349) were divided, according to size, into T2a (n = 238) and
T2b (n = 111), and survival was compared with those in T3 and T4. The 5-year sur-
vivals were 51.3%, 35.1%, 47.8%, and 25.3%, respectively. The difference between
T2a and T2b was statistically significant (log-rank P = .0170, Breslow P = .0055).
Conclusions: A tumor size of more than 5 cm in diameter was indicative of a poor
prognosis in non–small cell lung cancer, because patients with T2b tumors had a
significantly different survival from that of patients with T2a tumors, and the sur-
vival curve was located between those for patients with T3 and T4 tumors.
Consequently, T2b might be upgraded to at least T3.
Although many reports on the prognostic factors of non–small celllung cancer (NSCLC) have been published,1-6 and even though alarge tumor size has been thought to be an important factor in apoor prognosis, as shown in a recent review,7 in the TNM classi-fication provided by the International Union Against Cancer,tumor size has prognostic value only for small tumors. According
to the latest revision of the International System for Staging Lung Cancer in 1997,8
a cutoff point of 3 cm divides patients with T1 N0 M0, stage IA disease, who have
the best expectation for survival, from patients with T2 N0 M0, stage IB disease,
who have a significantly lower probability of survival.
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In this context, many reports have been published on the
poor survival for larger NSCLCs and better survival for
smaller tumors. Several important contributions appeared in
the 1960s and 1970s, when many studies considered size as
an autonomous factor in the prognosis: Steele9 in 1964,
Wellons and associates10 in 1968, Jackman and colleagues11
in 1969,Yashar and Yashar12 in 1975, and Soorae and Abbey
Smith13 in 1977 emphasized the very short survival in
patients with bulky tumors. The reports in the late 1970s by
Soorae and Abbey Smith13 and in 1984 by Ogata and
Naruke14 described the strong correlation between tumor
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diameter and lymph node involvement, with the frequency
of N2 and N3 increasing in conjunction with an increase in
tumor size. These reports raised the possibility that survival,
even in patients affected by bulky tumor, basically depended
on nodal involvement, because N0 and N1 tumors had a
clearly better prognosis than N2-N3 tumors.
However, surgical experience shows an adverse progno-
sis even for larger N0-N1 tumors that are completely
resected. This suggests that tumor size directly affects sur-
vival independent of lymph node involvement.
The aim of this study was to determine whether tumor
size can be considered an independent factor that affects sur-
vival in NSCLC. We analyzed 545 patients with tumors of
more than 3 cm in maximum diameter and their survival with
regard to size, nodal status, age, sex, pleural involvement,
operative procedure, histologic type, stage, and T factor.
Patients and Methods
Patients
From January 1985 to December 1994, a total of 1543 pulmonary
resections were performed at the National Cancer Center Hospital,
Tokyo, Japan. Of these, 545 patients (35.3%) who had NSCLC
more than 3 cm in maximum diameter were selected and included
in this retrospective study. Table 1 shows the patients’ characteris-
tics with 5-year survivals.
The analysis included patients with T2, T3, and T4 tumors who
underwent a complete resection by at least a lobectomy. Also
included were 8 patients (1.5%) who underwent a partial resection (5
of these were >70 years old). As for the mode of lymph node dissec-
tion, a systematic hilar/mediastinal dissection was performed in 455
patients (83.4%) and hilar dissection was performed in 65 (11.9%),
whereas 25 patients (4.6%) had no lymphadenectomy. Initially, all of
the patients were divided into 3 groups according to the tumor diam-
eter, regardless of tumor invasion of the surrounding organs: group A
(342 patients, 62.8%), with tumor from 3.1 to 5 cm; group B (146
patients, 26.8%), with tumor from 5.1 to 7 cm; and group C (57
patients, 10.5%), with tumors larger than 7 cm. As a consequence of
the results of the initial univariate analysis, they were divided into
only 2 groups: group A, with tumors ranging from 3.1 to 5 cm (342
patients, 62.8%), and group B+C (203 patients, 37.2%), with tumors
larger than 5 cm. Because of the small number of N3 tumors (18
patients, 3.3%), N2 and N3 were grouped together (166 patients, with
a cumulative rate of 30.5%). The degree of pleural involvement was
described in terms of a “P factor,” according to the following
Japanese definition: P0, no invasion of the visceral pleura; P1, sus-
pected invasion of, but not through, the visceral pleura; P2, invasion
through the visceral pleura; and P3, invasion of the chest wall,
diaphragm, mediastinal structures, or adjacent lobes. T, N, M, and the
stage of the disease were considered according to the 1987 TNM
classification of the International Union Against Cancer.15 Tumor his-
tologic type was categorized according to the World Health
Organization classification16 as adenocarcinoma, squamous cell car-
cinoma, adenosquamous cell carcinoma, or large cell carcinoma. 
Excluded from the analysis were patients with tumors smaller
than 3 cm (T1), patients with distant metastasis (stage IV), and
patients in whom pathologic examination disclosed infiltration of
TABLE 1. Patient characteristics and 5-year survivals 
Variables No. of patients (%) Five-year survival (%)
Sex
Male 440 (80.7) 42.1
Female 105 (19.3) 48.6
Age (y)
<50 57 (10.5) 47.4
50-59 123 (22.6) 56.1
60-69 218 (40.0) 42.2
>70 147 (27.0) 32.7
Histologic type
Adenocarcinoma 264 (48.4) 40.9
Squamous carcinoma 215 (39.4) 48.8
Large cell carcinoma 47 (8.6) 40.4
Adenosquamous carcinoma
Operative procedure 19 (3.5) 21.1
Pneumonectomy 126 (23.1) 31.8
Lobectomy 411 (75.4) 47.0
Partial resection 8 (1.5) 37.5
P factor
P0 209 (38.3) 48.3
P1 125 (22.9) 46.4
P2 39 (7.2) 30.8
P3 172 (31.6) 37.8
Stage
I 173 (31.7) 60.1
II 134 (24.6) 49.3
III 238 (43.7) 27.7
T factor
T2 349 (64) 46.1
T2a (<5 cm) 238 (43.7) 51.3
T2b (>5 cm) 111 (20.4) 35.1
T3 113 (20.7) 47.8
T4 83 (15.2) 25.3
Nodal status
N0 236 (43.3) 58.5
N1 143 (26.2) 42.0
N2+N3 166 (30.5) 22.9
Tumor size
Group A (<5 cm) 342 (62.8) 48.0
Group B+C (>5 cm) 203 (37.2) 35.5
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the bronchial resection margin, low-grade malignant tumors (car-
cinoids, adenoid cystic carcinomas, mucoepidermoid carcinomas),
sarcomas, carcinosarcomas, and bronchioloalveolar carcinomas.
Double primary tumors and Nx conditions were also excluded. 
Statistical Analysis17,18
The following 9 prognostic factors, which have been reported to
influence survival, were analyzed by univariate and multivariate
analyses: age, sex, histologic type, operative procedure, degree of
pleural involvement, tumor size, lymph node involvement, T fac-
tor, and stage. The Kaplan–Meier method was used to estimate
survival and its 95% confidence interval. The univariate statistical
comparison was made by the log-rank and Breslow tests; the day
of the operation was considered the beginning day for the analy-
sis, and all deaths, including 30-day postoperative deaths, were
included. For the multivariate analysis, the Cox proportional haz-
ard model19 was used to identify variables that were significantly
associated with survival. SPSS version 10 statistical software
(SPSS, Inc, Chicago, Ill) was used for the analysis.
Results
Univariate Analysis
The overall survival curve for all 545 patients is shown in
Figure 1, and the 5-year survival was 43%. On the basis of
the univariate analysis, a significantly worse prognosis was
found for patients more than 60 years old (log-rank P =
.0000; Breslow P = .0001), men (Breslow P = .0105), tumor
invasion through the visceral pleura and extending to the
parietal pleura (P2 and P3) compared with P0 (log-rank P =
.0442; Breslow P = .0126; Figure 2), pneumonectomy (log-
rank P = .0015; Breslow P = .0002), and an advanced stage
of disease (log-rank and Breslow P = .0000). There was no
evidence of statistically significant differences among the
histologic types.
Prognosis by Tumor Size 
Initially, a statistically significant difference was found between
groups A and B, with 5-year survivals of 48% and 37%, respec-
tively (log-rank P = .0377; Breslow P = .0085), and between
groups A and C, with 5-year survivals of 48% and 31.6% (log-
rank P = .0039; Breslow P = .0002), but not between groups B and
C (log-rank P = .1929; Breslow P = .0928) (Figure 3). 
Prognosis by Nodal Status 
The survival curves for patients with N0, N1, and N2+N3
disease showed a statistically significant difference among
the 3 levels of nodal involvement, with 5-year survivals of
58.5%, 42%, and 22.9%, respectively (log-rank and
Breslow P = .0000). 
Prognosis by Tumor Size in the Same Nodal Category 
Different tumor sizes (group A vs group B+C) were com-
pared within the same nodal category: N0, N1, and N2+N3.
A statistically significant difference was found by the
Breslow test in N0 (P = .0374; Figure 4) and in N2+N3 (P
= .0157; Figure 5), whereas no statistically significant dif-
ference was found in N1.
Prognosis by T Factor 
The 349 patients with T2 tumors were divided into 2 groups:
T2a, with tumors ranging from 3.1 to 5 cm, and T2b, with
tumors larger than 5 cm. The 5-year survivals for T2a, T2b,
T3, and T4 were 51.3%, 35.1%, 47.8%, and 25.3%, respec-
tively (Figure 6). Statistically significant differences were
Figure 1. Survival curve for 545 patients with tumors larger than 3
cm. The 5-year survival is 43%.
Figure 2. Survival according to the degree of pleural involvement.
The survival curves show a significantly worse prognosis for
tumor invading through the visceral pleura (P2) and the parietal
pleura (P3).













TX found between T2a and T2b (log-rank P = .0170; Breslow P
= .0055), between T2a and T4 (log-rank P = .0000; Breslow
P = .0000), and between T3 and T4 (log-rank P = .0037;
Breslow P = .0042). No difference was found between T2a
and T3 (log-rank P = .5316; Breslow P = .3257), T3 and T2b
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(log-rank P = .1645; Breslow P = .1975), or T2b and T4
(log-rank P = .0964; Breslow P = .0786).
Multivariate Analysis 
Of the variables that were entered in the multivariate
analysis (Table 2), sex, age, size, nodal status, histologic
type, and operative procedure were found to be signifi-
cantly related to survival.
Discussion 
In the TNM Classification for Lung Cancer, tumor size is
considered to affect the prognosis only for small tumors
(stage I, <3 cm), whereas larger sizes are not thought to
have a direct influence on survival, as reported in a recent
review by Mountain.20 In the advanced stage of the disease,
invasion of visceral pleura, associated atelectasis, obstruc-
tive pneumonia, and extension of tumor within the lung as
well as to adjacent structures and organs all represent local
progression and are responsible for a poor prognosis, rather
than tumor diameter. Therefore, tumor size has not been
considered to reflect locally advanced T status. On the other
hand, a strong correlation has been shown between tumor
size and lymph node involvement,13,14,21 with a higher per-
centage of N2 in larger tumors and a proportionally worse
prognosis for patients with N2 tumors.22-25
Our results show that tumor size directly affects survival,
with a significantly worse prognosis for tumors larger than 5
cm than for those ranging from 3 to 5 cm. We also found a
significantly poorer survival for patients with T2b tumors,
Figure 3. Survival curves according to tumor size. The 5-year survivals
for group A (3.1-5 cm), group B (5.1-7 cm), and group C (>7 cm) are 48%,
37%, and 31.6%, respectively. A statistically significant difference
was found between groups A and B (log-rank P = .0377, Breslow P =
.0085) and A and C (log-rank P = .0039, Breslow P = .0002), but not
between B and C (log-rank P = .1929, Breslow P = .0928).
Figure 4. Stratified analysis for patients with N0 disease (n = 236).
The 5-year survivals for tumors of 3.1 to 5 cm and more than 5 cm
are 61.9% and 51.3%, respectively. A statistically significant dif-
ference was found by the Breslow test (P = .0374).
Figure 5. Stratified analysis for patients with N2+N3 disease (n =
166). The 5-year survivals for tumors of 3.1 to 5 cm and more than
5 cm are 27.8% and 15.9%, respectively. A statistically significant
difference was found by the Breslow test (P = .0157).
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Figure 6. Survival curves according to T factor. The 5-year survivals for T2a (3.1-5 cm), T2b (>5 cm), T3, and T4 are
51.3%, 35.1%, 47.8%, and 25.3%, respectively. A statistically significant difference was found between T2a and T2b
(log-rank P = .0170, Breslow P = .0055), between T2a and T4 (log-rank and Breslow P = .0000), and between T3 and
T4 (log-rank P = .0037, Breslow P = .0042). No difference was found between T2a and T3, T3 and T2b, or T2b and
T4. *Statistically significant; —, not statistically significant.
TABLE 2. Multivariate analysis (Cox proportional hazard model)
Variables No. of patients (%) Five-year survival P value Risk
Sex
Male 440 (80.7) 42.1
Female 105 (19.3) 48.6 .013 0.699
Age (y) .000
<50 57 (10.5) 47.4
50-59 123 (22.6) 56.1 .486 0.859
60-69 218 (40.0) 42.2 .066 1.435
>70 147 (27.0) 32.7 .000 2.376
Size
3.1-5 cm 342 (62.8) 48.0
>5 cm 203 (37.2) 35.5 .002 1.430
Nodal status .000
N0 236 (43.3) 58.5
N1 143 (26.2) 42.0 .001 1.608
N2+N3 166 (30.5) 22.9 .000 2.399
Histologic type .000
Adenocarcinoma 264 (48.4) 40.9
Squamous carcinoma 215 (39.4) 48.8 .000 0.569
Adenosquamous carcinoma 19 (3.5) 21.1 .971 0.990
Large cell carcinoma 47 (8.6) 40.4 .293 0.805
Operative procedure .001
Pneumonectomy 126 (23.1) 31.8
Lobectomy 411 (75.4) 47.0 .000 0.612
Partial resection 8 (1.5) 37.5 .768 1.127














closer to that for patients with T4 tumors, with 5-year sur-
vivals of 35.1% and 25.3%, respectively. These results sug-
gest that tumor size may be considered an independent factor
in determining the prognosis, that tumor size is distinct from
other features characterizing T2, T3, and T4 status, and that
T2 tumors larger than 5 cm should be upgraded to at least T3.
Similar results were reported by Watanabe and associates,26
who found, in patients with T2 N0 M0 disease, 5-year sur-
vivals of 61.0% and 46.3% for tumors less than 5.0 cm and
more than 5.1 cm, respectively.
Although lymph node involvement has been shown to sig-
nificantly affect survival, this analysis found a significant
“additive” effect with tumor size, and no significant interac-
tion was found when both variables were considered together,
as confirmed by a generalized Wilcoxon test in a stratified
univariate analysis. Despite the relationship between size and
nodal status, with a cumulative worsening of the 5-year sur-
vival, tumor size has an independent effect on the prognosis.
In fact, the 5-year survival for N0 patients with tumors larger
than 5 cm (51.3%) is significantly less than that for tumors
smaller than 5 cm (61.9%). This finding supports the possi-
bility of autonomous spreading,13 which seems to follow
routes different from the more anatomic lymphatic routes.
These results are confirmed by the proportional hazard
model, in which the estimated relative risk associated with
size increases for tumors larger than 5 cm (risk = 1.430).
In conclusion, tumor size was studied independent of
other variables in T3 and T4 of the TNM classification and
was shown to affect survival independent of nodal metas-
tases. Tumor size appears to play a fundamental role in the
prognosis of lung cancer, and a new cutoff point of 5 cm
divides tumors larger than 3 cm into 2 groups with signifi-
cantly different survivals. In addition, the 5-year survival of
patients with T2 tumors larger than 5 cm (T2b) is between
those for patients with T3 and T4 tumors and actually closer
to that for patients with T4 tumors. Thus, T2 tumor larger
than 5 cm might be upgraded to at least T3 in the TNM clas-
sification.
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